Repare Therapeutics has three most cancers drug candidates within the clinic and one other one anticipated to enter Section 1 by the tip of this 12 months. The biotech goals to make sure it has sufficient money to help these applications, together with essentially the most superior of them which not too long ago misplaced its large pharma companion, so it’s implementing a company restructuring that cuts out preclinical and discovery work.
The company shakeup will lower about 25% of Repare’s workforce, largely these concerned in preclinical work, the corporate mentioned in its announcement after Wednesday’s market shut. Repare is headquartered in Montreal and in addition maintains operations in Cambridge, Massachusetts. Of Repare’s 179 complete workers as of February of this 12 months, 143 are concerned in R&D, in response to the corporate’s annual report.
Repare develops medicine that leverage an idea referred to as artificial lethality, by which a deficiency in a gene pair results in cell demise. A deficiency in a single gene isn’t sufficient to kill a cell. Repare’s small molecule medicine goal the opposite gene in a pair to set off cell demise. Essentially the most superior Repare program is camonsertib, a drug designed to inhibit the DNA injury response protein ATR.
Two years in the past, Roche paid $125 million up entrance for international rights to camonsertib, which on the time had reached Section 1/2 testing in a spread of tumor sorts. Repare received’t be getting the as much as $1.2 billion in milestone funds specified by that deal. In February, Repare disclosed the pharma big had determined to terminate the alliance after “a assessment of Roche’s pipeline and evolving exterior components.” A separate collaboration with Bristol Myers Squibb is ongoing. The Roche termination was efficient in Could. Camonsertib continues to be in Section 1/2 medical testing. A research of the drug as a monotherapy for non-small cell lung most cancers is enrolling sufferers with ATR-inhibitor sensitizing mutations; preliminary information are anticipated in 2025.
The Repare pipeline additionally consists of lunresertib, which blocks a goal referred to as PKMYT1. A Section 1 check of lunresertib together with camonsertib is underway on the really useful Section 2 dose in sufferers with ovarian and endometrial cancers. The corporate mentioned it expects to report information from this research within the fourth quarter of this 12 months, which may set the stage for a registrational research in 2025.
In the meantime, RP-1664, an inhibitor of PLK4, is in Section 1 testing. The corporate expects to advance this drug to a Section 1/2 medical trial enrolling pediatric sufferers with high-risk, recurrent neuroblastoma. RP-3647, Repare’s polymerase theta ATPase inhibitor, is on monitor to start a Section 1 dose-finding research within the fourth quarter of this 12 months.
In its report of second quarter 2024 monetary outcomes on Aug. 6, Repare mentioned its money place was $208.1 million, which it anticipated could be enough to fund operations into mid-2026. The board of administrators accepted the strategic reprioritization on Aug. 1, in response to an Aug. 28 Repare regulatory submitting. No point out of this company shake-up was made within the quarterly report. Repare expects to report a one-time money cost of $1.5 million to $2 million for termination advantages. The restructuring will save an estimated $15 million yearly, which extends Repare’s money runway into the second half of 2026, the corporate mentioned within the submitting.
“We acknowledge at the moment the extraordinary contributions and productiveness of our discovery crew, who’ve enabled the event of our deep, revolutionary medical portfolio,” Repare President and CEO Lloyd Segal mentioned in a ready assertion. “In our mission to quickly develop new, practice-changing therapies, we are going to extra totally dedicate our assets to our most promising and superior precision oncology applications to maximise worth for sufferers and for our shareholders.”
Illustration: Getty Pictures
